ECTRIMS 2016: Biogen Makes Headway in MS Remyelination Studies

Biogen has identified the type of MS patient likely to respond to its remyelination approach with the investigational MAb opicinumab, even though its Phase II SYNERGY trial missed its primary endpoint.